Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.

MLA

Ma, Ya-Fang, et al. “Oral Arsenic and Retinoic Acid for High-Risk Acute Promyelocytic Leukemia.” Journal of Hematology & Oncology, vol. 15, no. 1, Oct. 2022, p. 148. EBSCOhost, https://doi.org/10.1186/s13045-022-01368-3.

APA

Ma, Y.-F., Lu, Y., Wu, Q., Lou, Y.-J., Yang, M., Xu, J.-Y., Sun, C.-H., Mao, L.-P., Xu, G.-X., Li, L., Huang, J., Wang, H.-Y., Lou, L.-J., Meng, H.-T., Qian, J.-J., Yu, W.-J., Wei, J.-Y., Li, Z.-Y., Zhu, X.-L., … Zhu, H.-H. (2022). Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia. Journal of Hematology & Oncology, 15(1), 148. https://doi.org/10.1186/s13045-022-01368-3

Chicago

Ma, Ya-Fang, Ying Lu, Qian Wu, Yin-Jun Lou, Min Yang, Jie-Yu Xu, Cai-Hong Sun, et al. 2022. “Oral Arsenic and Retinoic Acid for High-Risk Acute Promyelocytic Leukemia.” Journal of Hematology & Oncology 15 (1): 148. doi:10.1186/s13045-022-01368-3.